Catalyst Pharmaceuticals' (CPRX) rare-disease platform now looks better than when I last covered it. Firdapse and Agamree are ...

Catalyst Pharmaceuticals has entered into a definitive agreement to be acquired by Angelini Pharma for $4.1b. The transaction has unanimous board approval and is expected to close in the third quarter ...

As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla., May 07, ...

Catalyst Pharmaceuticals, Inc.’s CPRX lead drug, Firdapse (amifampridine), is approved in the United States and Europe for the treatment of adult patients with Lambert-Eaton myasthenic syndrome (“LEMS ...

What Tools Were Used in the Studies for Lambert-Eaton Myasthenic Syndrome (LEMS)? Before describing how Firdapse was studied, it is important to understand the tools that were used in the studies.

New York, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Firdapse (amifampridine) - Drug Insight and Market Forecast - 2030 ...

Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Firdapse (Amifampridine) - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. Firdapse (amifampridine) ...

We issued an updated report on Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) on Jul 4. In November 2018, the company’s Firdapse (amifampridine) tablets obtained FDA approval for the treatment of Lambert ...

- Firdapse 2019 Net Product Revenues Expected to be Approximately $102 Million -Anticipates Full Year 2020 Firdapse Net Product Revenues to be in the Range of $135 million to $155 million - MuSK-MG ...

The FDA’s 2019 approval of Jacobus Pharmaceutical Co. Inc.’s Ruzurgi to treat children ages 6 to 17 with Lambert-Eaton myasthenic syndrome must be set aside because it violated the Orphan Drug Act in ...

We issued an updated research report on Catalyst Pharmaceuticals Inc. CPRX on Sep 7, 2020. Catalyst’s share price has declined 17.9% compared with the industry’s decline of 9% in the year so far. The ...